ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/urothelial/advanced-metastatic/subsequent
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Prostate and Urogenital / Urothelial - Advanced/metastatic / Subsequent
11
trial(s) found.
NCT06617169
Advanced
Phase 1
Recruiting
Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers (
MNPR101-Lu-1-01
)
177Lu-anti-uPAR radioconjugate
Bladder cancer
Colorectal cancer
Gastric cancer
Lung cancer
Ovarian cancer
Pancreatic cancer
Solid tumour
Triple-negative breast cancer
Urothelial carcinoma
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Breast cancer
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Urothelial carcinoma
Uterine serous carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06225596
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (
BT8009-230
)
bicycle toxin conjugate,NECTIN4-targeting
Urothelial carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05544552
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (
SURF301
)
FGFR3 inhibitor
Bladder cancer
Cancer
Carcinoma
FGFR3:alteration
Solid tumour
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Linear Clinical Research
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04879329
Advanced
Phase 2
Recruiting
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2 (
RC48G001
)
anti-ERBB2 antibody-drug conjugate
anti-PD-1 monoclonal antibody
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT04140526
Advanced
Phase 1 / Phase 2
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (
PRESERVE-001
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenoid cystic carcinoma
Breast cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Salivary gland cancer
Sarcoma
Small-cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2305 - New Lambton Heights - Newcastle Private Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT03821935
Advanced
Phase 1
Recruiting
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors (
M19-345
)
anti-GARP monoclonal antibody
anti-PD-1 monoclonal antibody
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05867303
Advanced
Phase 1
Active not recruiting
A Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Immunogenetic and Efficacy of RC198 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (
RC198-G001
)
undisclosed fusion protein
Clear cell renal cell carcinoma
Colorectal cancer
Head and neck squamous cell carcinoma
Melanoma
Non-small cell lung cancer
Urothelial carcinoma
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05562830
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A (
3475-04A
)
anti-PD-1 monoclonal antibody
Urothelial carcinoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05512377
Advanced
Phase 2
Active not recruiting
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours (
1403-0011
)
MDM2 inhibitor
Lung adenocarcinoma
NOT Urothelial carcinoma
Urothelial carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (8)
Active not recruiting (3)
Recruitment Country and State
QLD (9)
NSW (8)
VIC (7)
SA (5)
WA (4)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (4)
Phase 2 (3)
Phase 2 / Phase 3 (1)
Trial Type
Advanced (11)
Cancer Therapy Class
PD-1
55%
PD-1/PD-L1
55%
ERBB2
18%
NECTIN4
9%
PD-L1
9%
FGFR
9%
FGFR3
9%
CCR8
9%
CTLA4
9%
GARP
9%
ROR1
9%
MDM2
9%
Facility
4102 - Woolloongabba - Princess Alexandra Hospital (5)
2109 - North Ryde - Macquarie University Hospital (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4215 - Southport - Tasman Oncology (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4215 - Southport - Gold Coast University Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
2170 - Liverpool - Liverpool Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
6009 - Nedlands - One Clinical Research (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Urothelial carcinoma
Gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Thoracic cancer
Breast cancer
Upper gastrointestinal cancer
Non-small cell lung cancer
Colorectal cancer
Gastric cancer
Gastroesophageal cancer
Gynaecological cancer
Lower gastrointestinal cancer
Pancreatic cancer
Pancreatobiliary cancer
Head and neck cancer
Breast adenocarcinoma
Ovarian cancer
Triple-negative breast cancer
Cervical cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
HPV-related cancer
HPV16-positive cancer
Oesophageal cancer
Viral-related cancer
Clear cell renal cell carcinoma
Head and neck squamous cell carcinoma
Kidney cancer
Melanoma
Bladder cancer
Carcinoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Endometrial cancer
Endometrial carcinoma
Uterine serous carcinoma
FGFR3:alteration
Colorectal adenocarcinoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Adenoid cystic carcinoma
Cancer Solid tumour Carcinoma
Male genital cancers
Neuroendocrine carcinoma
Prostate cancer
Salivary gland cancer
Sarcoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Lung adenocarcinoma
Non-squamous non-small-cell lung cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy